Total Payments
$7,200
2024 Payments
$3,137
Companies
53
Transactions
263
Medicare Patients
3,120
Medicare Billing
$910,659
Payment Breakdown by Category
Food & Beverage$5,950 (82.6%)
Other$1,097 (15.2%)
Education$152.96 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,950 | 248 | 82.6% |
| Long term medical supply or device loan | $1,097 | 11 | 15.2% |
| Education | $152.96 | 4 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,444 | 33 | $0 (2024) |
| Celgene Corporation | $478.67 | 19 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $401.95 | 12 | $0 (2024) |
| PFIZER INC. | $360.31 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $338.66 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $334.31 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $244.54 | 7 | $0 (2024) |
| SOBI, INC | $205.73 | 5 | $0 (2024) |
| Gilead Sciences, Inc. | $202.87 | 9 | $0 (2024) |
| GENZYME CORPORATION | $188.33 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,137 | 110 | Novartis Pharmaceuticals Corporation ($736.00) |
| 2023 | $2,348 | 90 | Novartis Pharmaceuticals Corporation ($437.81) |
| 2022 | $1,280 | 49 | Novartis Pharmaceuticals Corporation ($270.20) |
| 2021 | $151.93 | 3 | E.R. Squibb & Sons, L.L.C. ($110.69) |
| 2020 | $43.80 | 2 | AbbVie Inc. ($24.39) |
| 2019 | $224.17 | 8 | Lilly USA, LLC ($111.32) |
| 2017 | $15.33 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15.33) |
All Payment Transactions
263 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/19/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $30.09 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $27.92 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/09/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: DESMOID TUMORS | ||||||
| 12/06/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $34.73 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: NONE | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.84 | General |
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.78 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: BioOncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.91 | General |
| Category: Hematology | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | AKEEGA (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Oncology | ||||||
| 11/01/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: DESMOID TUMORS | ||||||
| 10/30/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/28/2024 | Boston Scientific Corporation | TheraSphere Y90 Glass Microspheres 10 GBq (Device) | Food and Beverage | In-kind items and services | $37.65 | General |
| Category: TheraSphere_PI | ||||||
| 10/28/2024 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $25.72 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,216 | 64,592 | $2.2M | $542,025 |
| 2022 | 23 | 898 | 31,135 | $846,288 | $161,927 |
| 2021 | 16 | 526 | 18,719 | $614,026 | $129,212 |
| 2020 | 16 | 480 | 1,762 | $375,517 | $77,494 |
Total Patients
3,120
Total Services
116,208
Medicare Billing
$910,659
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 9,000 | $1.2M | $386,843 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 404 | $148,672 | $38,766 | 26.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 49 | 299 | $211,393 | $30,766 | 14.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 174 | 332 | $83,000 | $21,025 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 66 | 120 | $42,840 | $11,241 | 26.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 17 | 21,930 | $109,650 | $8,603 | 7.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 59 | 144 | $45,072 | $7,308 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 167 | 730 | $14,600 | $6,132 | 42.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 233 | $36,581 | $5,331 | 14.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 99 | $34,056 | $5,097 | 15.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $20,340 | $4,812 | 23.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 141 | 595 | $21,420 | $4,496 | 21.0% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 26 | 23,900 | $47,800 | $3,741 | 7.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $9,672 | $2,270 | 23.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 104 | $9,984 | $1,126 | 11.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 49 | $7,889 | $1,116 | 14.2% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 42 | 102 | $3,468 | $646.68 | 18.6% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 11 | 4,350 | $21,750 | $546.75 | 2.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 20 | 30 | $3,000 | $446.34 | 14.9% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 470 | $53,580 | $401.09 | 0.7% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 11 | 67 | $28,877 | $400.09 | 1.4% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 42 | 102 | $2,244 | $379.44 | 16.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 25 | $2,700 | $311.99 | 11.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 41 | 1,373 | $1,373 | $133.38 | 9.7% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 11 | 23 | $437.00 | $46.55 | 10.7% |
About Dr. Nikesh Jasani, M.D
Dr. Nikesh Jasani, M.D is a Hematology & Oncology healthcare provider based in Cypress, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215096912.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nikesh Jasani, M.D has received a total of $7,200 in payments from pharmaceutical and medical device companies, with $3,137 received in 2024. These payments were reported across 263 transactions from 53 companies. The most common payment nature is "Food and Beverage" ($5,950).
As a Medicare-enrolled provider, Jasani has provided services to 3,120 Medicare beneficiaries, totaling 116,208 services with total Medicare billing of $910,659. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Cypress, TX
- Active Since 12/08/2006
- Last Updated 10/07/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215096912
Products in Payments
- KISQALI (Drug) $973.89
- MYRISK (Device) $279.25
- REBLOZYL (Biological) $186.48
- Pomalyst (Drug) $179.31
- ENHERTU (Biological) $160.18
- OPDIVO (Biological) $152.14
- ERLEADA (Drug) $145.19
- Lenvima (Drug) $129.91
- myRisk (Device) $122.70
- OPDUALAG (Drug) $117.20
- clonoSEQ (Device) $112.51
- Trodelvy (Drug) $112.13
- KEYTRUDA (Biological) $111.47
- VERZENIO (Drug) $111.32
- ENJAYMO (Biological) $101.91
- BOSULIF (Drug) $100.75
- DOPTELET (Drug) $99.99
- Padcev (Drug) $98.00
- Enhertu (Drug) $96.01
- ULTOMIRIS (Biological) $91.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.